Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.34 |
| ▸ | CDK9 | P50750 | 5/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13520156 | 0.90 | NPY5R (0.32) | NPY5RHDAC1CCNT1CDK9EGFR | |
| SCHEMBL3127731 | 0.80 | NPC1 (0.33) | HDAC1MAPTTSHRMAPK1 | |
| SCHEMBL10018351 | 0.79 | NPY5R (0.32) | NPY5RHDAC1CCNT1CDK9EGFR | |
| SCHEMBL3375825 | 0.76 | TSHR (0.50) | NPY5RHDAC1MAPTPOLBCCNT1 | |
| SCHEMBL9166658 | 0.75 | NPY5R (0.42) | NPY5RHDAC1MAPTPOLBCCNT1 | |
| SCHEMBL3390402 | 0.73 | CCNT1 (0.46) | NPY5RHDAC1MAPTCCNT1CDK9 | |
| SCHEMBL10031393 | 0.73 | NPC1 (0.46) | MAPTHTTTSHRMAPK1 | |
| SCHEMBL20971749 | 0.72 | MAPT (0.41) | NPY5RHDAC1MAPTPOLBCCNT1 | |
| SCHEMBL13525456 | 0.72 | NPY5R (0.40) | NPY5RHDAC1MAPTPOLBCCNT1 | |
| SCHEMBL13913134 | 0.72 | TSHR (0.50) | NPY5RMAPTPOLBCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362464-B2 | Organic nanofiber structure based on self-assembled organogel, organic nanofiber transistor using the same, and method of manufacturing the organic nanofiber transistor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-01-29 | — | — | US | disclosed |
| US-20100006830-A1 | Organic semiconductor compound based on 2,7-bis-(vinyl)[1]benzothieno[3,2-b]benzothiophene, organic semiconductor thin film and transistor using the same and methods of forming the same | SAMSUNG ELECTRONICS CO., LTD. | 2010-01-14 | — | — | US | disclosed |
| US-20100006824-A1 | ORGANIC NANOFIBER STRUCTURE BASED ON SELF-ASSEMBLED ORGANOGEL, ORGANIC NANOFIBER TRANSISTOR USING THE SAME, AND METHOD OF MANUFACTURING THE ORGANIC NANOFIBER TRANSISTOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100006830-A1 | Organic semiconductor compound based on 2,7-bis-(vinyl)[1]benzothieno[3,2-b]benzothiophene, organic semiconductor thin film and transistor using the same and methods of forming the same | BPNT1, TST, SULT1E1 | NPY5R 4721/4885HDAC1 2032/4885MAPT 624/4885 |
| US-20100006824-A1 | ORGANIC NANOFIBER STRUCTURE BASED ON SELF-ASSEMBLED ORGANOGEL, ORGANIC NANOFIBER TRANSISTOR USING THE SAME, AND METHOD OF MANUFACTURING THE ORGANIC NANOFIBER TRANSISTOR | GAP43, NOTCH4, OGA | NPY5R 4480/4885HDAC1 4083/4885MAPT 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.